Brought to you by 
Genetix licenses Vpr gene technology from Theratechnologies
13 Jul 1999
Executive Summary
Genetix exclusively licensed Vpr gene technology for its LentiPak system from Theratechnologies and will make up-front, milestone, and royalty payments. Vpr products have potential cancer and cardiovascular applications.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com